Clinicopathologic features of advanced squamous NSCLC

Mark A. Socinski, Coleman Obasaju, David R Gandara, Fred R. Hirsch, Philip Bonomi, Paul Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Maurice Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather Wakelee, Carlos Mayo, Nick Thatcher

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations


Lung cancer remains the leading cause of cancer-related death worldwide. NSCLC accounts for more than 85% of all lung cancers, and the prognosis for advanced-stage disease is typically poor. In recent years, the importance of histologic subtypes of NSCLC has been recognized, and the distinction between squamous and other NSCLC histologic subtypes is now critical to patient management. Squamous cell lung cancer (sqCLC) represents approximately 25% to 30% of NSCLC. The prognosis for patients with advanced NSCLC is poorer for those with sqCLC than for those with adenocarcinoma. This is partly due to a number of clinical characteristics that distinguish sqCLC from other NSCLC histologic subtypes, such as smoking history, comorbid diseases, age, and molecular profile. Together, these factors make sqCLC an especially challenging disease to manage. Herein, we review some of the key clinicopathologic features of sqCLC. Understanding these features to optimally address many of the unique therapeutic challenges of this disease is likely to be central to ultimately improving outcomes for patients with squamous NSCLC.

Original languageEnglish (US)
Pages (from-to)1411-1422
Number of pages12
JournalJournal of Thoracic Oncology
Issue number9
StatePublished - 2016


  • Etiology
  • Histologic subtype
  • Squamous cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Clinicopathologic features of advanced squamous NSCLC'. Together they form a unique fingerprint.

Cite this